Apimeds Pharmaceuticals Files Q1 2025 10-Q

Ticker: APUS · Form: 10-Q · Filed: May 20, 2025 · CIK: 1894525

Apimeds Pharmaceuticals Us, INC. 10-Q Filing Summary
FieldDetail
CompanyApimeds Pharmaceuticals Us, INC. (APUS)
Form Type10-Q
Filed DateMay 20, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, quarterly-report, pharmaceuticals

TL;DR

Apimeds Pharma filed its Q1 2025 10-Q. Check financials.

AI Summary

Apimeds Pharmaceuticals US, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Delaware with its principal executive offices in Hopewell, New Jersey, operates in the Pharmaceutical Preparations industry. The filing was made on May 20, 2025, under SEC file number 001-42545.

Why It Matters

This filing provides investors with an update on Apimeds Pharmaceuticals' financial performance and operational status for the first quarter of 2025.

Risk Assessment

Risk Level: low — This is a routine quarterly filing providing standard financial and operational information.

Key Players & Entities

FAQ

What is the primary business of Apimeds Pharmaceuticals US, Inc.?

Apimeds Pharmaceuticals US, Inc. operates in the Pharmaceutical Preparations industry, with a Standard Industrial Classification code of 2834.

When was the quarterly period covered by this 10-Q filing?

The quarterly period ended on March 31, 2025.

On what date was this Form 10-Q filed with the SEC?

This Form 10-Q was filed on May 20, 2025.

What is the SEC file number for Apimeds Pharmaceuticals US, Inc.?

The SEC file number for Apimeds Pharmaceuticals US, Inc. is 001-42545.

Where are the principal executive offices of Apimeds Pharmaceuticals US, Inc. located?

The principal executive offices are located at 2 East Broad Street, 2nd Floor, Hopewell, New Jersey, 08425.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 20, 2025 regarding Apimeds Pharmaceuticals US, Inc. (APUS).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing